Vorinostat in combination with gemcitabine plus platinum in patients with advanced non-small-cell lung cancer: A phase I, dose-escalation study

被引：3
|
作者：
Misset, J.
Tredaniel, J.
Descourt, R.
Morot-Sibilot, D.
Zalcman, G.
Gachard, E.
Garcia-Vargas, J.
Rizvi, S.
Reiser, D.
Roben, L.
机构：
[1] Hop St Louis, Paris, France
[2] Inst Cancerol & Hematol, Brest, France
[3] DMAS Pneumol Oncol Thorac, Grenoble, France
[4] CHU Caen, F-14000 Caen, France
[5] MSD, Paris, France
[6] Merck Res Labs, Upper Gwynedd, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.14601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
14601
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE I DOSE-ESCALATION STUDY OF VORINOSTAT COMBINED WITH GEMCITABINE AND PLATINUM AGENTS IN ADVANCED NON-SMALL-CELL LUNG CANCER
    Descourt, R.
    Zalcman, G.
    Moro-Sibilot, D.
    Tredaniel, J.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Reiser, D.
    Roben, E.
    Rizvi, S.
    ANNALS OF ONCOLOGY, 2008, 19 : 111 - 111
  • [2] Phase I dose-escalation study of vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small-cell lung cancer (NSCLC)
    Teixeira, L.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J. L.
    Gachard, E.
    Rizvi, S.
    Roben, E.
    Zalcman, G.
    EJC SUPPLEMENTS, 2009, 7 (02): : 554 - 554
  • [3] Vorinostat in combination with gemcitabine and cisplatinum in patients with advanced non-small cell lung cancer (NSCLC): A Phase I dose-escalation study
    Tredaniel, J.
    Descourt, R.
    Moro-Sibilot, D.
    Misset, J.
    Gachard, E.
    Garcia-Vargas, J.
    Roben, E.
    Zalcman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study
    Reck, Martin
    Frickhofen, Norbert
    Cedres, Susana
    Gatzemeier, Ulrich
    Heigener, David
    Fuhr, Heinz-Georg
    Thall, Aron
    Lanzalone, Silvana
    Stephenson, Patricia
    Ruiz-Garcia, Ana
    Chao, Richard
    Felip, Enriqueta
    LUNG CANCER, 2010, 70 (02) : 180 - 187
  • [5] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    R D Kim
    S R Alberts
    C Peña
    I Genvresse
    A Ajavon-Hartmann
    C Xia
    A Kelly
    J E Grilley-Olson
    British Journal of Cancer, 2018, 118 : 462 - 470
  • [6] Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer
    Kim, R. D.
    Alberts, S. R.
    Pena, C.
    Genvresse, I.
    Ajavon-Hartmann, A.
    Xia, C.
    Kelly, A.
    Grilley-Olson, J. E.
    BRITISH JOURNAL OF CANCER, 2018, 118 (04) : 462 - 470
  • [7] A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer
    Kaira, Kyoichi
    Sunaga, Noriaki
    Yanagitani, Noriko
    Imai, Hisao
    Utsugi, Mitsuyoshi
    Shimizu, Yasuo
    Iijima, Hironobu
    Tomizawa, Yoshio
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Saito, Ryusei
    Mori, Masatomo
    ANTI-CANCER DRUGS, 2007, 18 (04) : 471 - 476
  • [8] A dose-escalation study of vorinostat in combination with radiotherapy for patients with non-small cell lung cancer
    Decker, R. H.
    Gettinger, S. N.
    Wilson, L. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Preliminary findings of a phase I dose-escalation study of sunitinib in combination with gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Frickhofen, N.
    Gatzemeier, U.
    Fuhr, H. G.
    Lanzalone, S.
    Wang, E.
    Chao, R.
    Felip, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 390 - 390
  • [10] A phase I dose escalation study of sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Frickhofen, N.
    Gatzemeier, U.
    Fuhr, H.
    Lanzalone, S.
    Lechuga, M. J.
    Wang, E.
    Chao, R.
    Felip, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345